Reply - 05/07/22
Doi : 10.1016/j.jaci.2022.03.027
James Baker, MD a 
, Kirsten Beyer, MD b, George du Toit, MB, BCh c, Wayne Shreffler, MD, PhD d, Kari R. Brown, MD, MSc e , David Norval f, Andrea Vereda, MD, PhD f, Daniel Adelman, MD e, g, Stacie M. Jones, MD h, Wesley Burks, MD i, Thomas Casale, MD j
, Kirsten Beyer, MD b, George du Toit, MB, BCh c, Wayne Shreffler, MD, PhD d, Kari R. Brown, MD, MSc e , David Norval f, Andrea Vereda, MD, PhD f, Daniel Adelman, MD e, g, Stacie M. Jones, MD h, Wesley Burks, MD i, Thomas Casale, MD j a Mary H. Weiser Food Allergy Center, University of Michigan, Ann Arbor, Mich
b Charité Universitãtsmedizin Berlin, Berlin, Germany
c Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
d Massachusetts General Hospital, Boston, Mass
e Aimmune Therapeutics, Brisbane, Calif
f Aimmune Therapeutics, London, United Kingdom
g Department of Medicine, University of California San Francisco, San Francisco, Calif
h University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark
i Department of Pediatrics, University of North Carolina Food Allergy Initiative, Division of Allergy, Immunology and Rheumatology, University of North Carolina at Chapel Hill, Chapel Hill, NC
j University of South Florida, Tampa, Fla
Le texte complet de cet article est disponible en PDF.
| Aimmune Therapeutics, a Nestlé Health Science company, sponsored the clinical trials and analyses described in the original article and provided financial support for the development of the original report. |
|
| Disclosure of potential conflict of interest: J. Baker reports advisory board and/or consulting fees from Aimmune Therapeutics. K. Beyer reports advisory board and/or consulting fees from Aimmune Therapeutics, ALK, Bausch & Lomb, Bencard, Danone, DBV, Hycor, Infectopharm, Mabylon, Meda Pharma, Mylan, and Nestle; speakers bureau fees from Aimmune Therapeutics, Allergopharma, Bencard, Danone, Di-Text, Hammer und Rall Media, Infectopharm, Meda Pharma, Med Update, Nestle, and Nutricia; and research grants from Aimmune, ALK, Danone, DBV, Good Mills, Hipp, Hycor, Infectopharm, Nutricia, ThermoFisher, and VDI. G. du Toit reports research grants to his institution and advisory board fees from Aimmune Therapeutics. W. G. Shreffler reports membership on the scientific advisory board of Aimmune Therapeutics and consultancies for DBV Technologies and Sanofi. K. R. Brown is an employee of Aimmune Therapeutics and was a subinvestigator in Aimmune clinical studies before employment by Aimmune; she has a patent pending for US patient 16/721,805. D. Norval and A. Vereda are employees of Aimmune Therapeutics. D. C. Adelman was an employee of Aimmune Therapeutics at the time of writing of the original article, and he is currently a consultant for Aimmune Therapeutics; he has patents pending (US 16/542,198; PCT/US2019/046706; US 16/721,805; and PCT/US2019/067634). A. W. Burks has received research support, advisory board fees, and lecture honoraria/consultation fees from Aimmune Therapeutics. S. M. Jones reports advisory board fees from Aimmune Therapeutics and Food Allergy Research and Education (FARE); personal fees from DBV Technologies; and clinical trial grants from Aimmune Therapeutics, DBV Technologies, Astellas, Sanofi, Regeneron, FARE, Genentech, and the National Institutes of Health–National Institute of Allergy and Infectious Disease. T. Casale reports grant funding from Aimmune Therapeutics and has acted as chief medical advisor for FARE. |
© 2022
American Academy of Allergy, Asthma & Immunology. Tous droits réservés.
Vol 150 - N° 1
P. 230-232 - juillet 2022 Retour au numéro
Article précédent
- Clarifying the categorization of anaphylaxis as an adverse event during oral immunotherapy
- Paul J. Turner, Nandinee Patel, Pablo Rodríguez del Río
- Corrigendum
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?